Compare HWBK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | SGHT |
|---|---|---|
| Founded | 1865 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.4M | 193.2M |
| IPO Year | N/A | 2021 |
| Metric | HWBK | SGHT |
|---|---|---|
| Price | $34.60 | $8.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.21 |
| AVG Volume (30 Days) | 6.4K | ★ 264.2K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ 259.86 | N/A |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $77,904,000.00 | $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.47 |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | ★ 45.83 | N/A |
| 52 Week Low | $25.21 | $2.03 |
| 52 Week High | $35.95 | $8.80 |
| Indicator | HWBK | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 75.39 | 66.52 |
| Support Level | $33.44 | $8.09 |
| Resistance Level | $34.20 | $8.68 |
| Average True Range (ATR) | 0.63 | 0.52 |
| MACD | 0.23 | -0.00 |
| Stochastic Oscillator | 95.35 | 72.32 |
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.